scholarly journals Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease

Hepatology ◽  
2009 ◽  
Vol 49 (6) ◽  
pp. 1926-1934 ◽  
Author(s):  
Kerry-Lee Milner ◽  
David van der Poorten ◽  
Aimin Xu ◽  
Elisabetta Bugianesi ◽  
James G. Kench ◽  
...  
Keyword(s):  
Fatty Acid ◽  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Fatty Acid Binding Protein ◽  
Fatty Acid Binding ◽  
Nonalcoholic Fatty Liver ◽  
Protein Levels ◽  
Acid Binding Protein

Adipocyte-fatty acid binding protein and non-alcoholic fatty liver disease in the elderly

2013 ◽  
Vol 26 (3) ◽  
pp. 241-247 ◽  
Author(s):  
Marco Masetti ◽  
Giampaolo Bianchi ◽  
Giordano Gianotti ◽  
Marco Giovagnoli ◽  
Luca Vizioli ◽  
...  
Keyword(s):  
Fatty Acid ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Fatty Acid Binding Protein ◽  
The Elderly ◽  
Fatty Acid Binding ◽  
Alcoholic Fatty Liver ◽  
Acid Binding Protein ◽  
Alcoholic Fatty Liver Disease

scholarly journals Relationship Between Fatty Acid Binding Protein 4 and Liver Fat in Individuals at Increased Cardiometabolic Risk

2021 ◽  
Vol 12 ◽  
Author(s):  
Ricardo Rodríguez-Calvo ◽  
Juan Moreno-Vedia ◽  
Josefa Girona ◽  
Daiana Ibarretxe ◽  
Neus Martínez-Micaelo ◽  
...  
Keyword(s):  
Fatty Acid ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Fatty Acid Binding Protein ◽  
Cardiometabolic Risk ◽  
Binding Protein ◽  
Liver Steatosis ◽  
Fatty Acid Binding ◽  
Acid Binding Protein

Background: Liver steatosis is considered the onset of the non-alcoholic fatty liver disease (NAFLD), a major public health challenge. Nevertheless, NAFLD detection and diagnosis remain a difficult task. Fatty acid binding protein 4 (FABP4) has been proposed as potential biomarker for the ectopic fat accumulation in non-adipose tissues, although its role reflecting liver steatosis in metabolic patients is not fully explored. The aim of this study was to assess the relationship between FABP4 and the fatty liver index (FLI) in metabolic patients and to evaluate its potential role in the fatty liver disease.Methods: A cross-sectional study involving 389 participants at increased cardiometabolic risk was performed. FLI was calculated in order to assess liver fatty disease and a FLI ≥ 60 was considered to define liver steatosis. The serum FABP4 levels were assessed by using a sandwich enzyme-linked immunosorbent assay. Multivariable regression models were used to examine the associations of FABP4 with fatty liver after adjusting for demographic and clinical characteristics.Results: Both, FLI and serum FABP4 levels were upregulated in diabetic, obese, and metabolic syndrome patients. Serum FABP4 levels were higher in individuals with liver steatosis. Serum FABP4 were robustly associated with FLI in metabolic patients in both linear and logistic regression analyses.Conclusion: Our findings show that the serum FABP4 is associated to liver steatosis in metabolic patients.

Sign in / Sign up

Export Citation Format

Share Document